News related to
China

Gold-backed cryptocurrencies have experienced significant declines following the announcement of sweeping tariffs by President Donald Trump. These digital assets, which are pegged to the value of physical gold, initially surged to record highs as investors sought safe havens. However, they have since retreated, mirroring the broader market sell-off.

On April 3, 2025, President Trump unveiled a series of reciprocal tariffs, imposing a minimum of 10% on global imports and up to 49% on certain countries, including Vietnam. This move prompted immediate reactions across financial markets, with the Dow Jones Industrial Average plunging over 1,000 points, the Nasdaq dropping 3%, and the S&P 500 slumping 2.7%. The technology sector was notably affected, with major companies like Apple, Amazon, and Meta experiencing substantial losses. citeturn0news27turn0news29

In the commodities market, gold initially rallied, reaching an all-time high of $3,167.84 per ounce. This surge was driven by investors seeking refuge amid escalating trade tensions. However, the precious metal’s value soon declined, with spot gold prices falling 1.4% to $3,090.00. This reversal was attributed to investors liquidating positions to cover losses in other asset classes. citeturn0search2turn0search4

Gold-backed cryptocurrencies, which are digital tokens pegged to the price of gold, mirrored this trajectory. PAX Gold and Tether Gold both saw declines, with PAXG trading at $3,047.64, down 2.44%, and XAUT at $3,047.16, down 2.51%. These movements reflect the broader market’s volatility and investors’ shifting sentiments.

The cryptocurrency market as a whole was not immune to the turmoil. Bitcoin, the largest cryptocurrency by market capitalization, fell to the $82,000 level, marking a significant drop from its previous position near $88,000 prior to the tariff announcements. Altcoins such as Ethereum and Solana also experienced declines, with Ethereum dropping over 6% to fall back under $1,800. citeturn0search17turn0search20

Analysts suggest that the aggressive nature of the tariffs has heightened fears of a global trade war, leading to increased market volatility. The tariffs’ impact extended beyond equities and cryptocurrencies, affecting commodities like crude oil, which saw a 6.4% decline. Bond yields also dropped as investors moved towards safer assets.

Central banks’ recent activities have also played a role in the gold market’s dynamics. In February, institutions such as Poland and China increased their gold reserves, contributing to the metal’s price movements. However, the current market conditions have overshadowed these factors, with immediate reactions to trade policies taking precedence.

The Nasdaq Composite Index entered bear market territory on Friday, April 4, 2025, closing over 20% below its December peak. This significant downturn was precipitated by President Donald Trump’s imposition of a 10% tariff on all imports to the United States, with additional substantial levies targeting technology-centric nations such as China, Taiwan, and Vietnam. China’s swift retaliation, announcing a 34% tariff on all U.S. imports, intensified fears of a global recession and inflationary pressures.

Major U.S. stock indices experienced sharp declines. The S&P 500 fell approximately 2.5%, while the Dow Jones Industrial Average dropped nearly 2.45%, shedding 994.46 points to close at 39,551.47. Technology stocks bore the brunt of the sell-off, with Apple Inc. shares declining over 4%, following a nearly 10% drop the previous day. Nvidia and Broadcom each lost more than 7%, and Tesla shares plummeted almost 10%.

The newly announced tariffs, dubbed “Liberation Day” tariffs by the administration, include a universal 10% tariff on all imports and higher targeted tariffs for numerous countries. Economists warn that these measures could disrupt global supply chains, particularly impacting the technology sector, which relies heavily on components from China and Taiwan. The Semiconductor Industry Association expressed concern that the tariffs could stymie growth and innovation within the industry.

International responses were swift. The European Union signaled readiness to implement countermeasures, while the International Monetary Fund cautioned that escalating trade tensions pose significant risks to global economic stability. In the U.S., political figures across the spectrum voiced apprehension. Senate Majority Leader Mitch McConnell and Senator Ted Cruz criticized the tariffs, warning of potential harm to American workers and farmers.

Despite a robust March jobs report indicating the addition of 228,000 new jobs and a slight uptick in unemployment to 4.2%, market sentiment remained negative. Investors are now looking to Federal Reserve Chair Jerome Powell’s upcoming speech for insights into potential monetary policy adjustments in response to the escalating trade conflict.

The CBOE Volatility Index, a measure of market anxiety, surged to levels not seen since August 2024, reflecting heightened investor concern. Oil prices also declined significantly due to fears of reduced global demand amid the escalating trade tensions.

President Trump defended the tariff strategy, asserting that the measures are necessary to address longstanding trade imbalances and would ultimately benefit the U.S. economy. He urged investors to view the market downturn as a wealth opportunity.

Beijing has announced the imposition of a 34% tariff on all imports from the United States, effective April 10, 2025, in direct response to the sweeping tariffs introduced by U.S. President Donald Trump. The Chinese Ministry of Finance stated that this measure aims to counteract what it perceives as unjust and protectionist policies from Washington.

This development follows President Trump’s declaration of “Liberation Day” on April 2, during which he unveiled a universal 10% tariff on all foreign imports, with higher rates for specific countries. China was notably targeted with an additional 34% tariff, bringing the total levy on Chinese goods to 54%. The U.S. administration justified these tariffs as necessary to rectify longstanding trade imbalances and to protect domestic industries.

In a statement, China’s Ministry of Finance condemned the U.S. actions, urging Washington to immediately withdraw the imposed tariffs to prevent further escalation. The ministry emphasized that China’s countermeasures are a legitimate response to safeguard its national interests and the multilateral trading system.

The U.S. tariffs have been met with criticism from various quarters. Economists have expressed concerns over the methodology used to calculate these tariffs, arguing that the approach is overly simplistic and could lead to unintended economic consequences. They warn that such measures might not effectively address trade deficits and could harm consumers through increased prices.

The business community is also bracing for the impact of these tariffs. In New York City, retailers are encouraging consumers to make purchases before the new tariffs lead to price increases. Products such as electronics, appliances, and automobiles are expected to see significant price hikes, prompting a surge in sales ahead of the tariff implementation.

China’s retaliatory tariffs are anticipated to affect a wide range of U.S. exports, including agricultural products, automobiles, and technology goods. This move is expected to have significant implications for American farmers and manufacturers who rely heavily on the Chinese market. Analysts predict that the escalating trade war could disrupt global supply chains and dampen economic growth in both countries.

The United States has imposed a 26% tariff on Indian imports, intensifying trade tensions between the two nations. This measure, announced by President Donald Trump on April 2, 2025, is part of a broader strategy targeting countries with which the U.S. has significant trade deficits. The baseline 10% tariff will take effect on April 5, with the additional 16% following on April 9.

President Trump has consistently criticized India’s trade policies, labeling the nation as a “tariff king” and a “big abuser” of tariffs. The administration justifies the new tariffs by pointing to the disparity between the U.S.’s 2.5% tariff on passenger vehicle imports and India’s 70% tariff on similar American products.

Indian officials have expressed mixed reactions to the announcement. A senior government representative described the development as a “mixed bag,” emphasizing that it is not perceived as a significant setback. The commerce ministry is currently evaluating the potential impact of these tariffs on the Indian economy.

The sectors most vulnerable to the increased tariffs include pharmaceuticals, textiles, and automotive parts, which constitute a substantial portion of India’s exports to the U.S. Analysts predict that these industries may experience a decline in competitiveness within the American market, potentially leading to decreased export volumes and revenue losses.

In an effort to mitigate the impact of the tariffs and foster better trade relations, India has proposed reducing tariffs on certain U.S. agricultural products, such as almonds, cranberries, and bourbon whiskey. This initiative aims to facilitate a more favorable trade agreement between the two countries.

Despite these conciliatory efforts, the U.S. proceeded with the tariff imposition. The move has elicited concerns among Indian policymakers and industry leaders about the potential escalation of a trade war and its ramifications on the domestic economy. The Confederation of Indian Industry has urged the government to engage in diplomatic negotiations to resolve the dispute amicably.

The global community is closely monitoring the situation, as the U.S.’s tariff measures have affected multiple countries, including China, the European Union, and Japan. The European Commission has criticized the tariffs as a severe blow to the global economy, while other nations have signaled intentions to retaliate or seek negotiations.

Pfizer has unveiled its new research and development centre in Beijing, marking a significant step in the company’s strategic expansion in China. The facility, located within the BioPark in the Beijing Economic-Technological Development Area , represents the pharmaceutical giant’s ongoing commitment to increasing its presence in the Chinese market. This development comes at a time when global healthcare companies are intensifying their focus on innovation in key Asian markets.

The opening of the R&D centre is expected to bolster Pfizer’s research capabilities, particularly in the development of cutting-edge treatments in areas such as oncology, vaccines, and rare diseases. The new centre will serve as a hub for collaborative efforts between Pfizer and local Chinese researchers, healthcare providers, and academic institutions. This collaboration is viewed as a strategic move to accelerate the discovery and delivery of new therapies tailored to both global and regional healthcare needs.

Pfizer’s decision to open a new R&D centre in Beijing underscores the company’s long-term investment in China’s growing pharmaceutical industry. It is also a response to the Chinese government’s push to modernise its healthcare infrastructure and increase the availability of advanced medical treatments to its population. China’s robust investment in healthcare innovation and its vast population present a significant opportunity for Pfizer to lead in areas of unmet medical need.

The Beijing facility will focus on the integration of new technologies, such as artificial intelligence and data analytics, into drug discovery and clinical development processes. These technologies are expected to streamline Pfizer’s ability to identify promising drug candidates more efficiently, reducing development timelines and improving outcomes for patients worldwide. The centre will also support the company’s efforts to create vaccines and treatments specifically designed for the Chinese market.

Local Chinese health experts have welcomed the initiative, highlighting the positive impact it is likely to have on the region’s pharmaceutical ecosystem. Collaborations between international pharmaceutical companies like Pfizer and domestic research institutions are seen as vital to addressing health challenges in China, including the increasing prevalence of chronic diseases and an ageing population. The government’s support of such ventures is also expected to foster a more innovative and competitive environment in the Chinese pharmaceutical sector.

Pfizer’s expansion into Beijing is not the company’s first move in the region. Over the past decade, the pharmaceutical leader has steadily increased its investments in China, with a particular focus on expanding its clinical trials and vaccine development operations. This new R&D centre further cements the company’s position as a key player in the Chinese healthcare landscape.

One of the critical drivers behind Pfizer’s decision to build the facility in Beijing is the strategic importance of the region’s role in global drug development. The Chinese market, one of the largest in the world, has seen rapid growth in demand for healthcare products, particularly in biotechnology, oncology treatments, and vaccines. With an increasingly affluent population, China’s demand for high-quality medical products has surged, presenting a strong business case for Pfizer to deepen its engagement with the market.

The opening of this facility aligns with Pfizer’s broader global strategy to strengthen its innovation pipeline and maintain its competitive edge in the pharmaceutical industry. The company has consistently emphasised the importance of R&D as a cornerstone of its business model, and this move further emphasises its commitment to discovering new therapies for complex diseases. The Beijing centre is expected to collaborate with Pfizer’s other global R&D hubs, contributing to a more interconnected and agile research network.

Pfizer’s global operations have also faced some challenges in recent years, particularly with the economic uncertainties brought on by the pandemic. However, the company’s strategy of investing in emerging markets like China reflects its resilience and focus on future growth. By establishing a physical presence in one of the world’s most dynamic pharmaceutical markets, Pfizer is positioning itself to tap into both immediate and long-term opportunities in China and beyond.

The Chinese government has been supportive of multinational companies that invest in high-tech industries such as pharmaceuticals and biotechnology. This policy environment has made it increasingly attractive for foreign companies to set up R&D centres and collaborate with Chinese firms. In return, China benefits from the influx of advanced medical technologies and expertise, further propelling its ambitions to become a leader in global healthcare innovation.

Pfizer’s Beijing R&D centre is part of a broader trend of Western pharmaceutical companies making significant investments in China. These companies are increasingly collaborating with local research institutions to foster innovation, improve patient care, and support the country’s healthcare development goals. Such investments are also aligned with China’s ongoing reforms aimed at modernising its healthcare system, ensuring broader access to innovative treatments, and addressing the nation’s rising health challenges.

The opening of the R&D centre also highlights Pfizer’s commitment to ensuring that new therapies developed in Beijing will be available not only to the Chinese market but also to the global community. With the centre poised to focus on therapies for diseases with high unmet needs, including cancer and infectious diseases, the potential for cross-border medical collaboration is immense. Pfizer’s ability to leverage the centre’s local expertise and technological advancements will play a crucial role in meeting both Chinese and global healthcare demands.

President Donald Trump has indicated that his first international trip in his second term will likely include visits to key countries in the Middle East, namely Saudi Arabia, the United Arab Emirates , and Qatar. While speaking to the press in the Oval Office, Trump suggested the visit could occur next month, though he noted it might be slightly delayed depending on diplomatic and scheduling considerations.

This trip is expected to be a crucial moment in Trump’s foreign policy, as it will focus on reinforcing the United States’ strategic relationships in the region, particularly in the wake of his administration’s efforts to reshape the dynamics of the Middle East through initiatives such as the Abraham Accords and military partnerships. The planned visit underscores the ongoing importance of these Gulf nations as key players in both regional and global geopolitical matters, including security, energy, and economic cooperation.

The president’s statement reflects the evolving nature of U.S. foreign policy in the Middle East, where traditional alliances have been reinforced while new partnerships, especially with the UAE and Bahrain, have emerged over the past few years. The Abraham Accords, signed in 2020, have opened new avenues for diplomatic engagement in the region, with several Arab countries normalising ties with Israel, a move that has significantly altered the political landscape.

Saudi Arabia, as a longstanding ally of the United States, remains at the heart of the Middle East’s geopolitics, particularly in relation to energy markets and security concerns regarding Iran’s growing influence. Trump’s administration was marked by its staunch support for the kingdom, including a controversial stance on the murder of journalist Jamal Khashoggi and its military cooperation in the region. A visit to Riyadh would likely reaffirm these strategic ties, especially as the U.S. continues to grapple with Iran’s nuclear ambitions and its role in regional instability.

The UAE has also become an increasingly influential partner, not only in terms of energy and security but also in fostering technological innovation and investment. In addition to hosting Israeli diplomatic missions following the Abraham Accords, the UAE has positioned itself as a hub for economic development, hosting major events like Expo 2020 Dubai and advancing its space exploration programme. Trump’s engagement with the UAE signals an ongoing commitment to strengthen ties with nations that have emerged as leaders in the Middle East’s economic diversification efforts.

Qatar, a key player in regional diplomacy and a host to the massive U.S. military base at Al Udeid, will also play a central role in Trump’s plans. As a small but influential country, Qatar has positioned itself as a mediator in various regional conflicts, often serving as an intermediary between conflicting parties in the region. Trump’s relationship with Qatar has been critical, particularly in relation to military cooperation and counter-terrorism efforts, and his visit would likely reaffirm the importance of these ongoing collaborations.

While the specifics of the trip remain unclear, the White House has made it known that the president’s travels will reflect the continued prioritisation of U.S. interests in the Middle East. Following years of tension over issues such as the U.S. withdrawal from Afghanistan and its approach to Iran, the Middle East remains a focal point of U.S. foreign policy. This visit could signal a shift towards a more engaged and active approach, particularly as the region faces new challenges ranging from economic instability to security threats from non-state actors.

Experts suggest that Trump’s trip will also serve as a signal to other global powers, particularly China and Russia, of the U.S.’s commitment to maintaining its influence in the Middle East. The region’s role in global energy production, combined with its strategic location at the crossroads of Europe, Africa, and Asia, makes it a critical area for U.S. interests. Trump’s visit is expected to focus on advancing energy partnerships, countering the growing influence of China in the region, and ensuring that U.S. military presence continues to be a stabilising factor in the face of Iranian provocations and broader geopolitical shifts.

Trump’s visit comes at a time when the Middle East is witnessing significant shifts in its diplomatic and economic alignments. Saudi Arabia, for example, has begun to recalibrate its foreign policy, striking deals with China and Russia, and there are signs that the kingdom is exploring new relationships outside its traditional Western alliances. Trump’s visit could also serve to counter these new trends, reinforcing U.S. leadership in the region.

The trip could be particularly significant for the future of U.S. relations with Israel. Although Israel’s peace agreements with several Arab states have altered the region’s political landscape, U.S. support for Israel remains a cornerstone of its Middle East policy. Trump’s visit will likely address how the U.S. plans to build on these agreements while navigating the evolving dynamics between Israel and its Arab neighbours.

As Trump prepares for his visit, discussions will also revolve around the broader implications of his foreign policy agenda. The Middle East is not only a region of military importance but also a key player in the global fight against terrorism, as well as in shaping energy markets and technological innovations. Trump’s emphasis on strengthening partnerships with countries like Saudi Arabia, the UAE, and Qatar will be crucial in setting the tone for the next phase of U.S. involvement in the region.

Foxconn, Apple’s primary manufacturing partner, plans to produce 25 to 30 million iPhones in India this year, more than doubling its output from the previous year. This move underscores Apple’s strategy to strengthen its manufacturing footprint in India and diversify its supply chain amid global uncertainties.

The Taiwanese contract manufacturer has been conducting trial runs at its facility in Bengaluru, Karnataka, aiming to meet Apple’s stringent quality standards and production targets. This initiative aligns with Apple’s broader objective to reduce reliance on Chinese manufacturing and mitigate risks associated with geopolitical tensions and supply chain disruptions.

Foxconn’s expansion in India is part of a larger trend of global tech companies seeking alternative manufacturing hubs. India’s Production-Linked Incentive scheme has been instrumental in attracting such investments by offering financial incentives to boost domestic manufacturing. In the fiscal year ending March 2023, Foxconn produced approximately ₹300 billion worth of iPhones, surpassing the PLI scheme’s cap of ₹200 billion, indicating the program’s success in scaling up production.

In addition to iPhone assembly, Apple is broadening its product manufacturing in India. A unit of Foxconn is set to commence the assembly of AirPods at a new factory near Hyderabad, Telangana, by early 2025, following successful trial productions. This diversification reflects Apple’s commitment to expanding its product assembly capabilities within the country.

However, the expansion has encountered challenges. Reports suggest that China is imposing restrictions on the movement of employees and specialized equipment essential for high-tech manufacturing to India and Southeast Asia. These measures appear aimed at limiting technology transfers and mitigating potential job losses, posing obstacles to Apple’s efforts to diversify its production bases.

Despite these hurdles, Apple’s manufacturing partners in India are making significant strides. Tata Electronics has acquired a 60% stake in Pegatron Technology India, which manages an iPhone plant near Chennai. This acquisition positions Tata as a formidable competitor to established players like Foxconn in the Indian iPhone manufacturing landscape.

The Indian government’s support has been pivotal in this expansion. Foxconn is establishing a mobile phone manufacturing plant in the Devanahalli Industrial Area, Bengaluru, with an investment of ₹21,911 crore. The company will receive incentives amounting to ₹6,970 crore under the Electronics System Design and Manufacturing policy, as announced by Karnataka’s Chief Minister.